Compare Live Nation Entertainment, Inc. (LYV) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs TransMedics Group Inc — how do they compare? Live Nation Entertainment, Inc. trades at $185.81 (market cap $42.71B), while TransMedics Group Inc trades at $87.25 (market cap $3.10B). The key difference: Live Nation Entertainment, Inc. is far larger — about 13.8× TransMedics Group Inc's market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| LYV | TMDX | |
|---|---|---|
Market Cap | $42.71B | $3.10B |
Sector | Industrials | Technology |
52-Week High | $186.59 | $150.42 |
52-Week Low | $125.61 | $61.99 |
Enterprise Value | $44.92B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Live Nation (LYV) trades at $184.65, showing minimal daily movement (+0.01%) amid strong analyst support with 87% buy ratings. The stock maintains a bullish technical outlook with key resistance at $186 and support at $181. Recent Q2 2026 earnings beat expectations with $1.05 EPS versus $0.66 estimate, driven by record concert attendance and international demand growth. Revenue reached $25.2B in 2025, though net margins remain thin at 0.51%.
The outlook remains positive given robust demand for live events and raised 2026 guidance, but high valuation multiples (P/E 117.5) and legal/regulatory risks warrant caution. Insider selling activity and negative ROE (-116.7%) highlight execution challenges despite strong top-line performance. Upside to consensus $209.54 target depends on margin expansion and debt management.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
